Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Klus Pharma Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter is handled by 1 distinct examiner and 1 distinct art unit. The company's current prosecution is concentrated in 1 specialized area of biotechnology. This focus suggests that the company's current intellectual property strategy is centered on this 1 pending office action within the patent office's biotech divisions.
The busiest examiner for the portfolio is ALLEN, MARIANNE P, who is overseeing 1 pending office action. This 1 pending office action accounts for the total workload for the company. With only this 1 distinct examiner involved, the prosecution process is currently centralized, requiring engagement with a specific set of examiner expectations. The alignment of the active workload with this 1 distinct art unit allows for a targeted approach to securing patent rights.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558201 | ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ALLEN, MARIANNE P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558201 | ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ALLEN, MARIANNE P | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558201 | ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ALLEN, MARIANNE P | 1647 | §102§103§112 | Non-Final OA | — | Pending | Oct 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial